Retina (Philadelphia, Pa.) · 2025
FLUOCINOLONE ACETONIDE IMPLANT IN THE TREATMENT OF RETINAL ANGIOPATHY MACULAR EDEMA IN ATTRV30M PATIENTS.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quintas Cales Sofia, Bragança Francisca Caiado, Marques João Heitor, Coelho João Magalhães, Menéres Maria João, Beirão João Melo
Аннотация
PURPOSE: To evaluate the effectiveness and safety of the fluocinolone acetonide implant (0.2 µ g/day fluocinolone acetonide, ILUVIEN) in macular edema due to retinal amyloid angiopathy in patients with hereditary transthyretin amyloidosis associated with the V30M mutation (ATTRV30M).
METHODS: Retrospective observational case series of ATTRV30M patients' eyes treated with the implant for macular edema, from January 2010 to December 2019. Best-corrected visual acuity, central foveal thickness, and intraocular pressure were measured at baseline, at 1 week, and at months 1, 3, 6, and 12.
RESULTS: Fifteen eyes of 15 ATTRV30M patients with fluocinolone acetonide implants were included. All patients had already received a liver transplant. All had already been submitted to cataract surgery: 87% had an Ahmed valve implant, and 80% were vitrectomized due to vitreous amyloidosis. A statistically significant improvement in best-corrected visual acuity and in central foveal thickness at all time points was found compared with baseline. There was no statistically significant difference in intraocular pressure during the follow-up.
CONCLUSION: Patients with macular edema due to retinal amyloid angiopathy treated with the fluocinolone acetonide implant showed sustained increased functional results and anatomical improvement compared with baseline.
METHODS: Retrospective observational case series of ATTRV30M patients' eyes treated with the implant for macular edema, from January 2010 to December 2019. Best-corrected visual acuity, central foveal thickness, and intraocular pressure were measured at baseline, at 1 week, and at months 1, 3, 6, and 12.
RESULTS: Fifteen eyes of 15 ATTRV30M patients with fluocinolone acetonide implants were included. All patients had already received a liver transplant. All had already been submitted to cataract surgery: 87% had an Ahmed valve implant, and 80% were vitrectomized due to vitreous amyloidosis. A statistically significant improvement in best-corrected visual acuity and in central foveal thickness at all time points was found compared with baseline. There was no statistically significant difference in intraocular pressure during the follow-up.
CONCLUSION: Patients with macular edema due to retinal amyloid angiopathy treated with the fluocinolone acetonide implant showed sustained increased functional results and anatomical improvement compared with baseline.